Antiplatelet Agents in the Perioperative Period

Antiplatelet agents in the perioperative period.

OBJECTIVE To determine the use of the 3 major classes of antiplatelet drugs (aspirin, thienopyridines, and glycoprotein IIb/IIIa inhibitors), their management in the perioperative period, and the risks associated with premature withdrawal. DATA SOURCES We reviewed the PubMed, EMBASE, and Cochrane databases using the terms antiplatelet agents in the perioperative period, antiplatelet agents an...

Perioperative management of antiplatelet agents.

Perioperative management of antiplatelet agents is a common challenge with the increased number of patients requiring long-term therapy following coronary stenting. Debate currently exists regarding if and when to discontinue antiplatelet therapy prior to elective surgery. The delicate balance between decreasing the risk of bleeding intraoperatively and minimizing the risk of stent thrombosis i...

Antiplatelet agents and perioperative bleeding.

PURPOSE To briefly review the risks, in patients presenting for surgery, associated with the available antiplatelet agents, and to present the principles that should guide the evaluation of these risks and how to manage them. METHODS A narrative review of the current medical literature in English and French. MAIN FINDINGS Antiplatelet agents [mainly acetylsalicylic acid, clopidogrel and gly...

New anticoagulants and antiplatelet agents in perioperative period: Recommendations and controversies!

Perioperative management of antiplatelet agents in noncardiac surgery.

It is common that patients who are scheduled for surgery are treated with antiplatelet agents (APAs) due to their wide indications. The management of these APAs in the perioperative period (acetylsalicylic acid alone, a thienopyridine alone or, in most cases, a combination of them) has a dual perspective: the risk of bleeding when the patient is operated under the effect of the APA against the ...